Cue Biopharma Inc (CUE)

$0.86 +0.16 (22.86%)
Market Cap 52.75M
Revenue (ttm) 9.29M
Net Income (ttm) -40.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -437.78%
Debt to Equity Ratio 0.51
Volume 6,287,500
Avg Vol 346,668
Day's Range N/A - N/A
Shares Out 75.35M
Stochastic %K 52%
Beta 1.43
Analysts Strong Sell
Price Target $4.00

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2680
Address:
40 Guest Street, Boston, United States
StockScanners
StockScanners Jul. 17 at 1:34 AM
$CUE Keep watch if this holds above .85
0 · Reply
GlynnBusson
GlynnBusson Jul. 17 at 12:56 AM
$CUE only need another 1400% to break even 😂
0 · Reply
MGeronimo
MGeronimo Jul. 16 at 8:17 PM
$CUE IN AT .87 5x NORMAL BUYING
1 · Reply
TotalAmateur
TotalAmateur Jul. 16 at 7:17 PM
$CUE mOS 32 mos (and counting) vs 12.3
1 · Reply
Invest2live
Invest2live Jul. 16 at 5:51 PM
$BDTX 21% already; congrats 🎈🎊🎉🌿 Check out $CUE and $LCTX and $TTD
1 · Reply
LewisDaKat
LewisDaKat Jul. 16 at 4:55 PM
News Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer https://marketwirenews.com/news-releases/cue-biopharma-reports-new-complete-response-and-conf-7897455408247626.html $CUE
0 · Reply
DARKP00L
DARKP00L Jul. 16 at 4:50 PM
$CUE 12:29 on Jul. 16 2025 Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer #tradeideas
0 · Reply
Invest2live
Invest2live Jul. 16 at 4:43 PM
$CUE 43% already; congrats 🎈🎊🎉🌿 Check out $TLRY and $NOTE
0 · Reply
notsurewhat
notsurewhat Jul. 16 at 4:42 PM
$CUE well im out had to break even GL
0 · Reply
notsurewhat
notsurewhat Jul. 16 at 4:36 PM
$CUE That’s what I was thinking after looking into it but idk much bout it! Gl
0 · Reply
Latest News on CUE
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 16, 2025, 8:00 AM EDT - 19 hours ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jul 1, 2025, 4:05 PM EDT - 15 days ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Jun 24, 2025, 4:48 PM EDT - 22 days ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 12, 2025, 4:05 PM EDT - 2 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 8, 2025, 8:00 AM EDT - 2 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

May 5, 2025, 10:00 AM EDT - 2 months ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 6:12 PM EDT - 3 months ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 15, 2025, 2:00 AM EDT - 3 months ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 10:23 PM EDT - 3 months ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Apr 14, 2025, 5:05 PM EDT - 3 months ago

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma to Host Business Update Call and Webcast

Apr 14, 2025, 5:02 PM EDT - 3 months ago

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 31, 2025, 4:20 PM EDT - 3 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 29, 2024, 4:30 PM EST - 8 months ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 8:00 AM EST - 8 months ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 4:05 PM EST - 8 months ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma Announces Strategic Organizational Transition

Nov 14, 2024, 8:00 AM EST - 8 months ago

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Nov 8, 2024, 1:30 PM EST - 8 months ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 10 months ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:26 PM EDT - 10 months ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Sep 26, 2024, 11:10 PM EDT - 10 months ago

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Sep 9, 2024, 8:00 AM EDT - 11 months ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 8:17 PM EDT - 11 months ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 19, 2024, 4:05 PM EDT - 11 months ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

May 8, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 9:43 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Feb 29, 2024, 10:00 AM EST - 1 year ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 22, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 11, 2023, 3:32 PM EST - 1 year ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 7, 2023, 8:00 AM EST - 1 year ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:05 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Cue Biopharma to Host Investor Call

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Investor Call

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023, 4:35 PM EDT - 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

May 8, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 11:00 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Cue Biopharma to Host Business Update Call and Webcast

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

Mar 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

Feb 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Feb 16, 2023, 10:30 AM EST - 2 years ago

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

Feb 16, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

Cue Biopharma to Present at Two February 2023 Scientific Conferences

Feb 1, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Two February 2023 Scientific Conferences

StockScanners
StockScanners Jul. 17 at 1:34 AM
$CUE Keep watch if this holds above .85
0 · Reply
GlynnBusson
GlynnBusson Jul. 17 at 12:56 AM
$CUE only need another 1400% to break even 😂
0 · Reply
MGeronimo
MGeronimo Jul. 16 at 8:17 PM
$CUE IN AT .87 5x NORMAL BUYING
1 · Reply
TotalAmateur
TotalAmateur Jul. 16 at 7:17 PM
$CUE mOS 32 mos (and counting) vs 12.3
1 · Reply
Invest2live
Invest2live Jul. 16 at 5:51 PM
$BDTX 21% already; congrats 🎈🎊🎉🌿 Check out $CUE and $LCTX and $TTD
1 · Reply
LewisDaKat
LewisDaKat Jul. 16 at 4:55 PM
News Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer https://marketwirenews.com/news-releases/cue-biopharma-reports-new-complete-response-and-conf-7897455408247626.html $CUE
0 · Reply
DARKP00L
DARKP00L Jul. 16 at 4:50 PM
$CUE 12:29 on Jul. 16 2025 Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer #tradeideas
0 · Reply
Invest2live
Invest2live Jul. 16 at 4:43 PM
$CUE 43% already; congrats 🎈🎊🎉🌿 Check out $TLRY and $NOTE
0 · Reply
notsurewhat
notsurewhat Jul. 16 at 4:42 PM
$CUE well im out had to break even GL
0 · Reply
notsurewhat
notsurewhat Jul. 16 at 4:36 PM
$CUE That’s what I was thinking after looking into it but idk much bout it! Gl
0 · Reply
KRF0817
KRF0817 Jul. 16 at 4:35 PM
$CUE How this isnt above 1 already is a gift.
0 · Reply
LegendaryCharts
LegendaryCharts Jul. 16 at 4:30 PM
$CUE could go for more
0 · Reply
LegendaryCharts
LegendaryCharts Jul. 16 at 4:30 PM
$CUE out , made 400$
0 · Reply
DARKP00L
DARKP00L Jul. 16 at 4:29 PM
$CUE this stock is drawing major attention! Keep watch for market moves!
0 · Reply
DARKP00L
DARKP00L Jul. 16 at 4:28 PM
$CUE momentum building! Stock attracting attention, could be a mover!
0 · Reply
LegendaryCharts
LegendaryCharts Jul. 16 at 4:28 PM
$CUE got some lotto
0 · Reply
Majid74
Majid74 Jul. 16 at 4:25 PM
$CUE Lfg🚀🚀
0 · Reply
notsurewhat
notsurewhat Jul. 16 at 4:25 PM
$CUE woah
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 16 at 12:41 PM
$CUE (+14.3% pre) Breakthrough: New Cancer Drug Shows 88% Survival Rate in Head and Neck Cancer Phase 1 Trial https://ooc.bz/l/70134
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 16 at 12:22 PM
$CUE Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer By Cue Biopharma, Inc. | July 16, 2025, 8:00 AM P1.4+
0 · Reply
Ralphbeach
Ralphbeach Jul. 10 at 3:57 PM
$CUE accumulation
3 · Reply